Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Justin Kucinski (NPI 1689000697)

Field	Value
Entity Type	Individual
Organization	Justin Kucinski
Address	100 E Carroll St
City	Salisbury
State	MD
ZIP	21801
Taxonomy	Internal Medicine Physician
NPI Enumerated	September 23, 2013

Payer Source	Total Paid
Medicare	$6.9M
Medicaid	$0

Key Findings

This provider is effectively single‑payer with respect to public programs: lifetime Medicare revenue is $6.9M and there is no Medicaid billing on file, so analyses of public-payer operations should focus on Medicare performance and exposure. The NPI was enumerated on 2013-09-23 (~13 years ago), indicating over a decade of billing history to inform trend and peer comparisons.

Revenue is highly concentrated in a small number of high-cost infusion drugs: the precomputed top‑3 Medicare codes account for 68.8% of this provider's total Medicare revenue, driven by J9271 ($3M, 42.9%), J9022 ($937K, 13.6%), and J9299 ($842.9K, 12.2%). This concentration points to a business model structured around administration of expensive oncologic biologics rather than broad primary-care procedural revenue.

The CPT/HCPCS mix and code descriptions signal an oncology-focused infusion operation: high-revenue immunotherapy and monoclonal antibody codes (J9271, J9022, J9299, J9144, J9173) appear alongside chemotherapy administration codes (96413, 96417, 96415), indicating regular IV immunotherapy/chemotherapy sessions and the infrastructure of an infusion suite. Although the provider taxonomy is Internal Medicine Physician, the procedure mix resembles specialty infusion or oncologic treatment delivery.

For several top drugs the provider is a national or specialty outlier, reflecting unusually large volumes: J9022 ranks #1 of 39 providers nationally and is labeled an extreme outlier, and J9271 ranks #5 of 1841 providers nationally (100th percentile; extreme outlier). These rankings indicate this provider is a dominant national administrator for specific immunotherapies, not merely a routine local prescriber.

Key infusion administration metrics also exceed peers, supporting the inference of a high-throughput infusion practice: 96413 ($133.5K, 1.9%) ranks #24 of 7514 providers (100th percentile; extreme outlier), while add-on infusion codes such as 96417 (rank #112 of 3014, 96th percentile; notably above typical) and 96415 (rank #229 of 4959, 95th percentile; notably above typical) are elevated. These administration-code standings corroborate significant chemotherapy/infusion throughput beyond just dispensing expensive drugs.

Office-based evaluation-and-management activity is substantial relative to national peers, consistent with ongoing cancer patient management: 99214 accounts for $126.3K (1.8%) and ranks #4938 of 479517 providers (99th percentile; extreme outlier), and 99215 also appears above typical volume. High E/M ranks alongside infusion activity suggest the practice combines procedural infusion services with frequent longitudinal patient follow-up.

The drug portfolio includes supportive care and biosimilars as complementary revenue lines, pointing to comprehensive oncology service delivery: Q5111 (pegfilgrastim-cbqv) contributes $118.6K and Q5118 (bevacizumab-bvzr biosimilar) contributes $99.6K, while J0897 (denosumab) contributes $183.5K. These codes indicate routine use of growth factors and bone-targeted agents commonly used in oncology care pathways, expanding revenue beyond checkpoint inhibitors.

From a business-risk and contracting perspective, dependence on Medicare and a narrow set of high-cost oncology agents creates concentration exposure: with 68.8% of Medicare revenue tied to the top three codes and no Medicaid billing, payer diversification is limited and negotiation or reimbursement shifts for those specific agents could materially affect revenue. Analysts should monitor utilization trends for J9271, J9022, and J9299 and compare local competitor capacity given the provider's extreme outlier status on multiple specialty drug codes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

61 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	68,800	$40	$3M
J9022	Injection, atezolizumab, 10 mg	14,640	$60	$937K
J9299	Injection, nivolumab, 1 mg	35,120	$20	$842.9K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	21,240	$40	$807.1K
J9173	Injection, durvalumab, 10 mg	6,640	$60	$411.9K
J0897	Injection, denosumab, 1 mg	9,660	$20	$183.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,270	$110	$133.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,360	$90	$126.3K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	1,100	$110	$118.6K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	4,150	$20	$99.6K

Showing 1–10 of 61

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 61 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Justin Kucinski — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

61 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	60	15,000	$40	$787.6K
J9299	6	20	24,080	$20	$660.6K
J9022	1	10	10,070	$60	$646.8K
J9144	6	30	11,970	$40	$493.5K
J9173	1	10	4,790	$60	$297.9K
J0897	65	340	3,600	$20	$114.4K
Q5118	3	10	3,970	$20	$101.8K
Q5111	4	10	930	$110	$92.7K
J0881	29	60	30,420	$1	$76.4K
J1437	34	50	2,800	$20	$75.1K

Showing 1–10 of 61

Related Providers

Other providers that share a Tax Identification Number (TIN) with Justin Kucinski, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tidalhealth Nanticoke, Inc	DE	General Acute Care Hospital	$0	$19.2M
Tidalhealth Specialty Care, LLC	MD	Medical Specialty Clinic/Center	$0	$11.7M
Tidalhealth Physician Network, Inc.	DE	Family Medicine Physician	$0	$8.7M
Tidalhealth Peninsula Regional, Inc.	MD	General Acute Care Hospital	$0	$7.6M
Tanya Clifford	MD	Nurse Practitioner	$2.9M	$0
Tidalhealth Physician Network, Inc.	DE	Family Medicine Physician	$0	$2.9M
Ivonne Herrera	DE	Rheumatology Physician	$2.7M	$0
Rabindra Paul	MD	Infectious Disease Physician	$2.1M	$0
Muhammad Siddique	MD	Medical Oncology Physician	$1.6M	$0
Kazi Khan	MD	Nephrology Physician	$1.6M	$0

Nearby Providers

Other providers in the same ZIP code as Justin Kucinski, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Emergency Service Associates PA	MD	Emergency Medicine Physician	$0	$24.6M
Hudson Health Services, Inc.	MD	Substance Abuse Rehabilitation Facility	$0	$23.1M
Bnj Health Services Inc Salisbury	MD	Substance Use Disorder Rehabilitation Clinic/Center	$0	$10.3M
Ydiprmc LLC	MD	Urgent Care Clinic/Center	$0	$7.3M
Cnp Operating Co LLC	MD	Multi-Specialty Clinic/Center	$0	$7.3M
Cove Recovery, LLC	MD	Addiction (Substance Use Disorder) Counselor	$0	$5.2M
Gateway Pediatrics, LLC	MD	Pediatrics Physician	$0	$5.1M
Go-getters Inc	MD	Community/Behavioral Health Agency	$0	$5M
Wicomico County Health Department	MD	Public Health or Welfare Agency	$0	$4.9M
Delmarva Radiology P.A.	MD	Diagnostic Ultrasound Physician	$0	$4.3M

Justin Kucinski — Billing Profile & Reimbursement Data

Sign up for Justin Kucinski — Billing Profile & Reimbursement Data policy alerts

Justin Kucinski — Billing Profile & Reimbursement Data

Sign up for Justin Kucinski — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References